Learn About SNMMI
The bi-partisan Facilitating Innovative Nuclear Diagnostics (FIND) Act will ensure patient access to these imaging procedures.
Act Now!
Hear from SNMMI leadership, researchers, and patient advocates about what they're up to at the 2024 Annual Meeting.
View SNMMI-TV
Jun 12, 2024
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others earlier this week at its 2024 Annual Meeting in Toronto, Ontario. Themed “Inn
Read More
Jun 11, 2024
A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Mee
A comparative analysis between FAPI and 18F-FDG PET/CT for the systemic staging of newly diagnosed breast cancer shows that FAPI PET/CT is more accurate in staging patients. Nearly 20 percent of patients were restaged by FAPI PET/CT, indicating the r
Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides thelatest news and information to save you time and keep you informed on our profession.
SIGN UP TODAY
Looking for a healthcare facility that treats cancer using nuclear medicine therapies? The Society of Nuclear Medicine and Molecular Imaging designates medical centers that offer nuclear medicine therapy for patients with specific types of cancer. Check out SNMMI’s Therapy Centers of Excellence page to find sites near you.
Find Facilities
With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field.
Learn More
Supporting transformative nuclear medicine imaging and radiopharmaceutical therapy research that one day may be able to cure cancer.
SNMMI designated Radiopharmaceutical Therapy Centers of Excellence have affirmed that they have the training, personnel, equipment, and experience needed to manage patients requiring radiopharmaceutical therapy.
This book of protocols is created specifically for technologists it harmonizes with the accepted guidelines for the procedures included but is written as a complementary reference source to serve the practical needs of technologists. End of Translation It will assist technologists in providing the best possible patient care and image quality.
Founded in 1960, The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. JNM includes hot topics and state-of-the-art reports as well as clinical and basic science research in oncology, theranostics, neurology, cardiology, and radiation biology.
Subscribe
JNMT is the only peer-reviewed publication dedicated to nuclear medicine technology. Published quarterly, each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Current credentialing, continuing education and licensure requirements are reported regularly.
SNMMI is the preeminent provider of information and resources to the experts who are implementing and pioneering these lifesaving approaches to medicine.
Join SNMMI